


# Introduction to Pharmacology II- Pharmacokinetics

**PROF DR MAHMOUD  
KHATTAB**

# Aspects of Drug Pharmacokinetics (ADME)

---



# Drug Absorption


## Active vs. Passive

### ■ Active transport:

- Carrier-mediated
- Energy-dependent
- Against conc gradient
- Shows carrier saturation kinetics

### □ Passive transport

- Energy-independent
- No carrier involved
- Along conc gradient
- No saturation kinetics



# Drug Absorption

---

## ■ **Facilitated Diffusion**

- Protein carrier-mediated transport
- Saturable, selective
- Energy-independent
- Transport from higher to lower concentration, i.e., concentration gradient is the driving force

## ■ **Endocytosis:**

- Phagocytotic uptake of membrane-bound particles
- Pinocytosis of particles into the cells as vesicles that undergo lysosomal digestion or fusion

# Drug Absorption

## Factors Affecting Absorption


---

### ■ Effect of pH

- Only non-ionized fraction of drugs (acids or bases) is absorbed
- Non-ionised/ionised fraction is determined by the pH of absorption site & drug  $pK_a$  according to Henderson-Hasselbalch:

$$pH = pK_a + \log \frac{\text{non-protonated}}{\text{protonated}}$$

- If  $pH < pK_a \rightarrow$  protonated forms predominate
- If  $pH > pK_a \rightarrow$  non-protonated forms predominate



Absorption of  
basic/acidic  
drugs in GIT??

# Factors Affecting GIT Absorption

---

## ■ Blood Flow To Absorptive Site:

- Greater blood flow raises absorption
- Intestine has greater BF than stomach

## ■ Total Surface Area of Absorptive Site:

- Intestinal microvilli increases surface area to 1000-fold that of the stomach favoring intestinal absorption

## ■ Contact Time at Absorptive Site:

- Diarrhea reduces absorption
- Accelerated *gastric emptying* → faster delivery to intestinal large surface → increased absorption


# Factors Affecting GIT Absorption

---

- **Food:** Presence of food in the gut reduces/delays drug absorption from GIT
  - Increased splanchnic blood flow during eating increases drug absorption
  - Ionized drugs as tetracycline can form insol complexes with  $\text{Ca}^{2+}$  in food/milk
- **Formulation Factors:**
  - Solid dosage forms dissolution & sol are essential
  - Aqueous solutions are absorbed more quickly than tablets or suspensions


# BIOAVAILABILITY

- ❑ Fraction of a drug reaching systemic circulation after a particular route
- ❑ First pass metabolism, i.e., rapid hepatic metabolism, reduces bioav. (lidocaine, propranolol, nitrates)
- ❑ Drug solubility
- ❑ Chemical instability in gastric pH (penicillin G, insulin)
- ❑ Drug formulation: Standard & SR formulations





# First Pass Metabolism & Enterohepatic Circulation



# Routes of Drug Delivery

Parenteral  
(IV)




Inhaled



Oral



Transdermal



Topical



Parenteral  
(SC, IM)



Rectal



# Routes of Administration

Route	Advantages	Disadvantages
<b>Enteral</b>	Simple, no pain, convenient	Labile to 1 <sup>st</sup> pass metabolism & gastric acid, slow effect
<b>Parenteral</b>	Fast effect, high bioavailability, NOT labile to 1 <sup>st</sup> pass metabolism & gastric acid	Infection, pain, fear, need for skill, irreversible, rapid reactions
<b>Mucous membrane</b>	Fast effect, NOT labile to 1 <sup>st</sup> pass metabolism & gastric acid, minor systemic effect Simple, no pain, convenient	Applicable to only few drugs
<b>Transdermal</b>	Fast effect, NOT labile to 1 <sup>st</sup> pass metabolism & gastric acid Good for prolonged regimen	Only highly lipophilic drugs, slow effect, may be irritant

# Routes of Administration

---

- Other Routes include:
- Intranasal Route for systemic administration of drugs as clacitonin as an alternative for parenteral route
- Rectal route using suppository has the advantage of administering to drugs to unco-operative patients like children
  - Rectal route has only ~ 50% first-pass metabolism

# Volume of Drug Distribution

## Water Body Compartments


- Drugs may distribute into
- **Plasma (Vascular) Compartment:**

- Too large mol wt
- Extensive plasma protein binding
- Heparin is an example

- **Extracellular Fluid**

- ✓ Low mol wt drugs able to move via endothelial slits to interstitial water
- ✓ Hydrophilic drugs cannot cross cell membrane to the intracellular water


- **Total Body Water;** Low mol wt hydrophobic drugs distribute from interstitial water to intracellular



# Factors Affecting Distribution

## ■ *Capillary permeability*

- Endothelial cells of capillaries in tissues other than brain have wide slit junctions allowing easy movement of drugs
- Brain capillaries have no slits between endothelial cells, i.e.e., tight junction or blood brain barrier
- Only carrier-mediated transport or highly lipophilic drugs enter CNS
- Ionised or hydrophilic drugs can't get into the brain



# Barriers to Drug Distribution

---

## ❑ Blood-Brain barrier:

- ✓ Inflammation during meningitis or encephalitis may increase permeability into the BBB of ionised & lipid-insol drugs

## ❑ Placental Barrier:

- ✓ Drugs that cross this barrier reaches fetal circulation
- ✓ Placental barrier is similar to BBB where only lipophilic drugs can cross placental barrier



# Factors Affecting Distribution

## ■ Blood Flow (Tissue Perfusion):

- The greater the blood flow to a tissue, the faster and more distribution occurs from the plasma to the interstitial fluid
- Thus, Drugs will be distributed more rapidly to liver, brain & kidney more than muscles, skin, or fat depot (more cardiac output)


## □ Plasma Protein Binding:

- Many drugs bind reversibly to plasma proteins especially albumin  $D + \text{Albumin} \leftrightarrow D\text{-Albumin (Inactive)} + \text{Free } D$
- Only free drug can distribute, binds to receptors, metabolized and excreted



# Clinical Significance of Albumin Binding

- **Class I:** dose < available albumin binding sites (most drugs)
- **Class II:** dose > albumin binding sites (e.g., sulfonamide)
- Drugs of class II displace Class I drug molecules from binding sites → more therapeutic/toxic effect
- In some disease states → change of plasma protein binding
- In uremic patients, plasma protein binding of acidic drugs is reduced
- Plasma protein binding prolongs duration



# Selective Distribution of Drugs

- ❑ Kidney: Metallothionin leads to accumulation of metals like lead, cadmium & mercury
- ❑ Eye: Retinal malanin has affinity for drugs like chlorpromazine (& phenothiazines) & chloroquine leading to their accumulation
- ❑ Fat: Highly lipid-sol drugs tend to accumulate in body fat
- ❑ Bone can accumulate agents like tetracycline, lead, and cisplatin
- ❑ Lungs (the whole cardiac output)
  - Basic amine lipophilic drugs with  $pK_a > 8$  tend to accumulate in the lungs
  - Herbicides like paraquat tend to deposit in lung as well

# Apparent Volume of Distribution

---

## Volume of Distribution $V_D$

$$V_D = \text{Dose/Plasma Concentration}$$

- ❑ The volume (non-real) required to contain the total amount of absorbed drug in the body at a uniform concentration equivalent to that in plasma at steady state
- ❑ Units: L and L/Kg
- ❑ Drugs retained in the intravascular space have the lowest  $V_D$  values
- ❑ An extensively distributed drug like amiodarone has  $V_D$  of 60 L/Kg (4200 L/70 Kg)
- ❑ In general, larger  $V_D$  leads to prolonged duration ( $t_{1/2}$ )

# Drug Elimination

## Renal Excretion

---

- **Glomerular filtration** depends on:

- Renal blood flow & GFR; direct relationship
- Plasma protein binding; only free unbound drugs are filtered

- **Tubular Secretion** in the proximal renal tubule mediates raising drug concentration in PCT lumen

- ✓ Organic anionic & cationic transporters (OAT & OCT) mediate active secretion of anionic & cationic drugs
- ✓ Passive diffusion of uncharged drugs
- ✓ Facilitated diffusion of charged & uncharged drugs
- ✓ Plasma protein binding has ONLY slight effect because of the fast removal of unbound drug from peritubular capillaries
- ✓ Penicillin is an example of actively secreted drugs

# Drug Elimination

## Renal Excretion

---

### ■ Tubular re-absorption in DCT:

- Because of water re-absorption, urinary D concentration increases towards DCT favoring passive diffusion of un-ionized lipophilic drugs
- It leads to lowering urinary drug concentration
  - Urinary pH trapping:
  - Chemical adjustment of urinary pH can inhibit or enhance tubular drug reabsorption
  - For example, aspirin overdose can be treated by urine alkalinization with Na Bicarbonate (ion trapping) and increasing urine flow rate (dilution of tubular drug concentration)
  - Ammonium chloride can be used as urine acidifier for basic drug overdose treatment

# Drug Elimination


## ❑ Pulmonary excretion of drugs into expired air:

- Gases & volatile substances are excreted by this route
- No specialized transporters are involved
- Simple diffusion across cell membrane predominates
- It depends on:
  - ✓ *Drug solubility in blood*: more sol gases are slowly excreted
  - ✓ *Cardiac output* rise enhances removal of gaseous drugs
  - ✓ *Respiratory rate* is of importance for gases of high blood solubility

## ❑ Biliary excretion of few drugs into feces

- Such drugs are secreted from the liver into the bile by active transporters, and then into duodenum
- Examples: digoxin, steroid hormones, some anticancer agents
- Some drugs undergo enterohepatic circulation back into systemic circulation

# Drug Distribution and Clearance



# Clearance



- Clearance (CL) is the volume of blood/fluid cleared of drug per unit time
- It is ability of kidney, liver and other organs to eliminate drug from the bloodstream
- Units are in L/hr or L/hr/kg
- Used in determination of maintenance doses
- Drug metabolism and excretion are often referred to collectively as clearance
- The endpoint is reduction of drug plasma level
- *Clearance (total) = renal clearance + Hepatic clearance + others*
- Hepatic, renal and cardiac failure can each reduce drug clearance and hence increase elimination  $T_{1/2}$  of the drug
- **CL =  $kV_D$** , k: elimination rate constant



# Metabolism & Excretion Kinetics

- Elimination (metabolism + excretion) of most drugs follow first-order kinetics at therapeutic dose level
- Amount of drug cleared in a given unit of time is directly proportional to the concentration of the drug according to Michaelis-Menten (linear) kinetics:
- Only few drugs (e.g., phenytoin, alcohol) show saturation clearance (Zero-order, non-linear) kinetics
- Clearance mechanisms become saturated at therapeutic level, and clearance remain constant even with increased drug plasma level
- SLOW ELIMINATION at therapeutic levels leads to toxic reactions

$$E = \frac{V_{\max} \times C}{k_m + C}$$



# Loading Dose

- Loading Dose = Target Plasma C x VD
- What is the loading dose required for drug A if:
  - target concentration is 10 mg/L
  - VD is 0.75 L/kg, patient's weight is 75 kg

## Answer

- $VD = 0.75 \text{ L/kg} \times 75 \text{ kg} = 56.25 \text{ L}$
- Target Conc. = 10 mg/L
- $\text{Dose} = 10 \text{ mg/L} \times 56.25 \text{ L} = 562.5 \text{ mg}$

# Maintenance Dose

---


- **Maintenance Dose**

=  $CL \times \text{target steady state drug concentration}$


- The units of CL are in L/hr or L/hr/kg
- Maintenance dose will be in mg/hr
- Total daily maintenance dose = multiplying by 24

# Half-Life and Elimination Rate Constant (k)

- Half-life is the time taken for the drug concentration to fall to half its original value
- The elimination rate constant (k) is the fraction of drug removed per unit time




**Elimination Time  $\sim 4 t_{1/2}$**



# Steady-State

- Steady-state occurs after a drug has been given for approximately 4-5  $t_{1/2}$
- At steady-state the rate of drug administration equals the rate of elimination
- Plasma concentration after each dose is approximately the same



# Importance of Steady State (SS)

---

- At SS Rate in = Rate Out
- Steady state is reached usually within 4 – 5 half-lives at linear kinetics
- It is important for drug concentrations interpretation in:
  - Therapeutic Drug Monitoring (TDM)
  - Evaluation of clinical response